Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine - Strong Outlook for 2025
information fournie par Boursorama CP 27/03/2025 à 17:45
Ajoutez Boursorama à vos sources préférées

2024 Full-year results and business update


– Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part expected in Q2 2025

– Randomization in Phase II part of the Phase I/II trial evaluating TG4050 in head and neck cancer patients due to be completed in Q4 2025


– New trial with individualized cancer vaccine planned to start in Q4 2025 in a second indication

– Business funded until the end of April 2026

Conference call scheduled today at 6 p.m. CET (in English). See details below.



.../...

Valeurs associées

TRANSGENE
0,7110 EUR Euronext Paris -0,28%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
90,09 +0,72%
CAC 40
8 509,64 +0,28%
TOTALENERGIES
76,42 +1,12%
Or
4 042,68 0,00%
EUR/USD SPOT
1,1529 0,00%
Chargement...

Pages les plus populaires

L'offre BoursoBank